ClinicalTrials.gg

Program

odronextamab

Also written as “Odronextamab” and “Odronextamab multiple dose levels”.

Its studies are mostly in Lymphoma, B-Cell · Lymphoma, Follicular · Lymphoma, Large B-Cell, Diffuse · Lupus Nephritis · Lymphoma, Non-Hodgkin, led by Regeneron Pharmaceuticals.

Furthest: phase 3, since Oct 13, 20238 company-led studies, 6 open or runningNext primary completion: Feb 29, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals86 open or runningphase 3since Oct 13, 2023Nov 7, 2014Feb 29, 2028phase 3 · NCT06091254

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 7, 2014First study: phase 1 study in Lymphoma, Non-HodgkinFirst studyNCT02290951 · 200 enrolled · United States, France, Germany and more
  2. Jan 5, 2016Phase 1 study in RecurrenceNCT02651662 · 105 enrolled · United States, Austria, Germany and more
  3. Mar 14, 2019Phase 2 study in Lymphoma, B-CellNCT03888105 · 515 enrolled · United States, Australia, Canada and more
  4. Oct 13, 20232 phase 3 studiesNCT06091865, NCT06091254
  5. Nov 20, 2023Phase 3 study in Lymphoma, FollicularNCT06149286 · 580 planned · United States, Australia, Austria and more
  6. Dec 29, 2023Phase 3 study in Lymphoma, B-CellNCT06230224 · 216 enrolled · Argentina, Australia, Brazil and more
  7. May 8, 2025Phase 1 study in Lupus NephritisNCT06975787 · 90 planned · United States, France, Germany and more
  8. Nov 12, 2026Primary completion moved from 2028-02-07 to 2028-02-29Date moved laterphase 3 · +1 months · NCT06091254

Ahead

  1. Feb 29, 2028Primary completion: phase 3 study in Lymphoma, FollicularNCT06091254
  2. Mar 30, 2028Primary completion: phase 3 study in Lymphoma, Large B-Cell, DiffuseNCT06091865
  3. May 29, 2028Primary completion: phase 3 study in Lymphoma, B-CellNCT06230224
  4. Sep 10, 2029Primary completion: phase 1 study in Lupus NephritisNCT06975787

TargetBeta

CD3E →MS4A1 →read by rule
“B-lymphocyte antigen CD20 binding agent; T cell surface glycoprotein CD3 binding agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
mosunetuzumabruleHoffmann-La Rochephase 314
glofitamabruleHoffmann-La Rochephase 313
epcoritamabruleGenmabphase 313
TQB2825Sino Biopharmaceuticalphase 35
Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492AstraZenecaphase 22
GSK5926371GlaxoSmithKlinephase 22
REGN9220ruleRegeneron Pharmaceuticalsphase 21
Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543ruleJohnson & Johnsonphase 13

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06975787Lupus Nephritis · United States, France, Germany and more1RecruitingSep 10, 202990
NCT06230224Lymphoma, B-Cell · Argentina, Australia, Brazil and more3Active, not recruitingMay 29, 2028216
NCT06149286Lymphoma, Follicular · United States, Australia, Austria and more3RecruitingApr 30, 2031580
NCT06091865Lymphoma, Large B-Cell, Diffuse · United States, Australia, Austria and more3RecruitingMar 30, 2028904
NCT06091254Lymphoma, Follicular · United States, Australia, Austria and more3RecruitingFeb 29, 2028822
NCT03888105Lymphoma, B-Cell · United States, Australia, Canada and more2Active, not recruitingJun 17, 2026515
NCT02651662Recurrence · United States, Austria, Germany and more1CompletedApr 29, 2026105
NCT02290951Lymphoma, Non-Hodgkin · United States, France, Germany and more1CompletedAug 21, 2025200

How it is read

Names in the registry

  • “Odronextamab”, 6 entries
  • “Odronextamab multiple dose levels”, 2 entries
  • “odronextamab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.